Epi CanaryEpi Canary
  • Home
  • Feed
  • Synthesis
  • Assessments
  • Scopes
  • Reliability
  • Sources
Epi Canary — Epidemic IntelligenceEvidence-led epidemic intelligence. Source-attributed evidence.
Arcede logoMade by Arcede
← Scopes/
Novel Coronavirus SurveillanceHealth
  • Overview
  • Synthesis
  • Assessments
  • Evidence

Public note

For situational awareness and research transparency. Not medical advice.

Synthesis · Novel Coronavirus Surveillance

MERS camel-to-human confirmed in Somalia; BA.3.2 wastewater data absent; no novel sarbecovirus emergence signal.

Continuous monitoring of SARS-CoV-2 variant evolution, immune escape mutations, and signals of novel coronavirus emergence in animal reservoirs.

Updated Apr 22, 2026

Synthesis

DepthL3
L1

Key findings

Three hypotheses track BA.3.2 pediatric hospitalization burden, absence of novel sarbecovirus/merbecovirus with H2H transmission, and BA.3.2 wastewater elevation. ProMED captured MERS camel-to-human transmission in Somalia (Apr 22) — an established zoonotic pathway, not a novel CoV emergence event; neutral for the no-novel-emergence hypothesis. WHO DON (Apr 13) noted SARS-CoV-2 activity increases broadly consistent with prior seasonal patterns, providing marginal support for BA.3.2 wastewater hypothesis.

L2

Technical analysis

ProMED returned a MERS-CoV Somalia camel-to-human event (Apr 22), which is within the known merbecovirus surveillance envelope. This does not trigger the "novel sarbecovirus or merbecovirus with H2H chains" invalidation criterion. WHO DON Apr 13 global COVID situation update describes SARS-CoV-2 activity increases broadly consistent with expected patterns — weakly supportive of the BA.3.2 wastewater hypothesis but not definitively so. GISAID, genomic-surveillance, and EARS-Net (timeout) provide no variant frequency data this cycle.

PubMed returned one article on COVID-19 and Leydig cell function (neutral to all active hypotheses). ProMED and Africa CDC remain functional. EARS-Net is stale (1.2× expected cadence, last timeout Apr 21). PubMed is stale at 8.1% ok ratio with persistent timeout errors. GISAID and genomic-surveillance are inactive — the two sources most capable of confirming BA.3.2 wastewater dynamics are dark.

L3

Full appendix

BA.3.2 wastewater hypothesis (hyp:novel-coronavirus:2026-06-30:2026-04-13, conf 5): No wastewater monitoring data from any of the 14 target countries has entered the evidence stream. The WHO DON Apr 13 activity increase mention is consistent with but does not confirm BA.3.2-driven elevation. Horizon is Jun 30; roughly 10 weeks to resolution. GISAID inactive status is the key constraint — variant frequency data would be decisive.

BA.3.2 pediatric skew (hyp:novel-coronavirus:180d:002c9624b6, conf 6): No new age-stratified hospitalization data from any national surveillance dataset this cycle. Hypothesis rests on Apr 20 reports of pediatric skew. No confirming or refuting national registry data has appeared.

No novel H2H sarbecovirus/merbecovirus (hyp:novel-coronavirus:2026-12-31:7a27b533eb, conf 7): MERS Somalia is established merbecovirus camel-to-human — a known spillover pathway, not H2H transmission. The confidence in absence of novel emergence holds. Structural T5 surveillance gaps (GISAID inactive, genomic-surveillance inactive, ProMED intermittent) are the standing caveat.

02

Scope signals

Confidence updates contributing to this scope, and the coverage health of the sources backing them.

Confidence updates

HypothesisPriorDirectionMagnitudeReasoning
BA.3.2 will show documented excess pediatric hospitalization burden vs adult rate in at least one national surveillance dataset by Sep 30 2026.6neutral0.05No age-stratified hospitalization data this cycle
No novel sarbecovirus or merbecovirus with sustained human-to-human transmission declared via WHO DON or equivalent PHEIC-class authority through 2026-12-31.7neutral0.05MERS Somalia is established pathway, not novel H2H emergence
BA.3.2 ("Cicada") will cause a detectable wastewater elevation (≥20% increase from Q1 2026 baseline) in ≥3 of the 14 monitored countries by 2026-06-30, driven by immune escape from prior SARS-CoV-2 immunity.5support0.10WHO DON Apr 13 activity uptick mildly consistent with BA.3.2 circulation

Coverage

No coverage table published.